{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:19:04Z","timestamp":1765808344580,"version":"3.37.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"China\u2019s National Natural Science Foundation","doi-asserted-by":"crossref","award":["82300240 & 82170205","82300240 & 82170205"],"award-info":[{"award-number":["82300240 & 82170205","82300240 & 82170205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05819-4","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T04:01:28Z","timestamp":1717387288000},"page":"3105-3119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients"],"prefix":"10.1007","volume":"103","author":[{"given":"Mingyue","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"5819_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317","journal-title":"Blood"},{"key":"5819_CR2","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N et al (2022) Phase II study of Venetoclax added to Cladribine Plus Low-Dose Cytarabine Alternating with 5-Azacitidine in older patients with newly diagnosed Acute myeloid leukemia. JCO 40:3848\u20133857","journal-title":"JCO"},{"key":"5819_CR3","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH (2023) Acute myeloid leukaemia. Lancet 401:2073\u20132086","journal-title":"Lancet"},{"key":"5819_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/blood-2007-12-128918","volume":"112","author":"DI Marks","year":"2008","unstructured":"Marks DI, P\u00e9rez WS, He W, Zhang M-J, Bishop MR, Bolwell BJ et al (2008) Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 112:426\u2013434","journal-title":"Blood"},{"key":"5819_CR5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41409-022-01674-x","volume":"57","author":"R Devillier","year":"2022","unstructured":"Devillier R, Galimard J-E, Labopin M, Blaise D, Raiola AM, Pavlu J et al (2022) Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transpl 57:1421\u20131427","journal-title":"Bone Marrow Transpl"},{"key":"5819_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-016-0248-3","volume":"9","author":"MT Rubio","year":"2016","unstructured":"Rubio MT, Savani BN, Labopin M, Piemontese S, Polge E, Ciceri F et al (2016) Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. J Hematol Oncol 9:25","journal-title":"J Hematol Oncol"},{"key":"5819_CR7","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.31941","volume":"125","author":"N Santoro","year":"2019","unstructured":"Santoro N, Labopin M, Ciceri F, Van Lint MT, Nasso D, Blaise D et al (2019) Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. Cancer 125:1499\u20131506","journal-title":"Cancer"},{"key":"5819_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","volume":"116","author":"DI Marks","year":"2010","unstructured":"Marks DI, Wang T, P\u00e9rez WS, Antin JH, Copelan E, Gale RP et al (2010) The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia in first and second complete remission. Blood 116:366\u2013374","journal-title":"Blood"},{"key":"5819_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/bmt.2011.69","volume":"47","author":"SM Luger","year":"2012","unstructured":"Luger SM, Ringd\u00e9n O, Zhang M-J, P\u00e9rez WS, Bishop MR, Bornhauser M et al (2012) Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transpl 47:203\u2013211","journal-title":"Bone Marrow Transpl"},{"key":"5819_CR10","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/bloodadvances.2018021980","volume":"2","author":"M Eapen","year":"2018","unstructured":"Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM et al (2018) Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv 2:2095\u20132103","journal-title":"Blood Adv"},{"key":"5819_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL et al (2017) Myeloablative Versus reduced-intensity hematopoietic cell transplantation for Acute myeloid leukemia and myelodysplastic syndromes. JCO 35:1154\u20131161","journal-title":"JCO"},{"key":"5819_CR12","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","volume":"35","author":"N Kr\u00f6ger","year":"2017","unstructured":"Kr\u00f6ger N, Iacobelli S, Franke G-N, Platzbecker U, Uddin R, H\u00fcbel K et al (2017) Dose-reduced Versus Standard Conditioning followed by Allogeneic Stem-Cell Transplantation for patients with myelodysplastic syndrome: a prospective Randomized Phase III Study of the EBMT (RICMAC trial). JCO 35:2157\u20132164","journal-title":"JCO"},{"key":"5819_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","volume":"108","author":"R Martino","year":"2006","unstructured":"Martino R (2006) Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836\u2013846","journal-title":"Blood"},{"key":"5819_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/sj.leu.2404010","volume":"20","author":"BL Scott","year":"2006","unstructured":"Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al (2006) Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20:128\u2013135","journal-title":"Leukemia"},{"key":"5819_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.V91.3.756","volume":"91","author":"S Slavin","year":"1998","unstructured":"Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with Lethal Cytoreduction for the treatment of Malignant and Nonmalignant Hematologic diseases. Blood 91:756\u2013763","journal-title":"Blood"},{"key":"5819_CR16","doi-asserted-by":"publisher","first-page":"638253","DOI":"10.3389\/fimmu.2021.638253","volume":"12","author":"JCY Ho","year":"2021","unstructured":"Ho JCY, Cheung SKF, Lui Z, Tang IWH, Yang W, Ip P et al (2021) Revisit of Optimal Donor Number Estimation in the Hong Kong Bone Marrow Donor Registry. Front Immunol 12:638253","journal-title":"Front Immunol"},{"key":"5819_CR17","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","volume":"124","author":"Y Luo","year":"2014","unstructured":"Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J et al (2014) T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 124:2735\u20132743","journal-title":"Blood"},{"key":"5819_CR18","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/bjh.17978","volume":"196","author":"Y Wu","year":"2022","unstructured":"Wu Y, Lai X, Shi J, Tan Y, Zhao Y, Yu J et al (2022) Effect of donor characteristics on T cell-replete haploidentical stem cell transplantation over the last 10 years at a single institution. Br J Haematol 196:1225\u20131238","journal-title":"Br J Haematol"},{"key":"5819_CR19","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.bbmt.2019.05.031","volume":"25","author":"E Karam","year":"2019","unstructured":"Karam E, Laporte J, Solomon SR, Morris LE, Zhang X, Holland HK et al (2019) Who is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: a young HLA-Mismatched Haploidentical relative or an older fully HLA-Matched sibling or unrelated Donor? Biol Blood Marrow Transplant 25:2054\u20132060","journal-title":"Biol Blood Marrow Transplant"},{"key":"5819_CR20","doi-asserted-by":"crossref","unstructured":"Mehta RS, Ramdial J, Marin D, Alousi A, Kanakry CG, Champlin RE et al (2023) Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Transplantation and Cellular Therapy. ; 29: 377.e1-377.e7","DOI":"10.1016\/j.jtct.2023.03.028"},{"key":"5819_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"Y-J Chang","year":"2017","unstructured":"Chang Y-J, Wang Y, Liu Y-R, Xu L-P, Zhang X-H, Chen H et al (2017) Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol 10:134","journal-title":"J Hematol Oncol"},{"key":"5819_CR22","doi-asserted-by":"publisher","unstructured":"Chang Y, Zhao X, Wang Y, Liu Y, Xu L, Zhang X et al (2017) Effects of pre- and post\u2010transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen\u2010matched or mismatched related donor allografts. Am J Hematol 92. https:\/\/doi.org\/10.1002\/ajh.24910","DOI":"10.1002\/ajh.24910"},{"key":"5819_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41409-017-0018-z","volume":"53","author":"J Gauthier","year":"2018","unstructured":"Gauthier J, Poir\u00e9 X, Gac A-C, Leclerc M, Guillaume T, Chalandon Y et al (2018) Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin\u2019s lymphoma undergoing allogeneic haematopoietic cell transplantation\u2014a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transpl 53:400\u2013409","journal-title":"Bone Marrow Transpl"},{"key":"5819_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41409-023-02027-y","volume":"58","author":"E Maffini","year":"2023","unstructured":"Maffini E, Ngoya M, Galimard J-E, Harbi S, Kr\u00f6ger N, Platzbecker U et al (2023) Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl 58:1033\u20131041","journal-title":"Bone Marrow Transpl"},{"key":"5819_CR25","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/sj.leu.2403092","volume":"17","author":"H Tamaki","year":"2003","unstructured":"Tamaki H, Ikegame K, Kawakami M, Fujioka T, Tsuboi A, Oji Y et al (2003) Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia 17:2052\u20132054","journal-title":"Leukemia"},{"key":"5819_CR26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.bbmt.2015.04.012","volume":"21","author":"K Ikegame","year":"2015","unstructured":"Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y et al (2015) Unmanipulated Haploidentical reduced-intensity stem cell transplantation using Fludarabine, Busulfan, low-dose antithymocyte globulin, and steroids for patients in non\u2013complete remission or at high risk of Relapse: a prospective Multicenter Phase I\/II study in Japan. Biol Blood Marrow Transplant 21:1495\u20131505","journal-title":"Biol Blood Marrow Transplant"},{"key":"5819_CR27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.bbmt.2006.06.007","volume":"12","author":"H Ogawa","year":"2006","unstructured":"Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al (2006) Unmanipulated HLA 2\u20133 Antigen-Mismatched (Haploidentical) Stem Cell Transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 12:1073\u20131084","journal-title":"Biol Blood Marrow Transplant"},{"key":"5819_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al (2015) National Institutes of Health Consensus Development Project on Criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging Working Group Report. Biol Blood Marrow Transplant 21:389\u2013401e1","journal-title":"Biol Blood Marrow Transplant"},{"key":"5819_CR29","doi-asserted-by":"crossref","unstructured":"EBMT\u2009\u2013\u2009NIH (National Institutes of Health)\u2009\u2013\u2009CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force, on behalf of the EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the, Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE et al (2018) EBMT\u2009\u2013\u2009NIH\u2009\u2013\u2009CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. ; 53: 1401\u20131415","DOI":"10.1038\/s41409-018-0204-7"},{"key":"5819_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl 40:381\u2013387","journal-title":"Bone Marrow Transpl"},{"key":"5819_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statist Med 18:695\u2013706","journal-title":"Statist Med"},{"key":"5819_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"5819_CR33","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229\u20134361","journal-title":"Eur Heart J"},{"key":"5819_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41409-023-01925-5","volume":"58","author":"Y-Q Sun","year":"2023","unstructured":"Sun Y-Q, Zhang X-H, Jiang Q, Jiang H, Chang Y-J, Wang Y et al (2023) Comparison of haploidentical hematopoietic stem cell transplantation with chemotherapy in older adults with acute myeloid leukemia. Bone Marrow Transpl 58:491\u2013497","journal-title":"Bone Marrow Transpl"},{"key":"5819_CR35","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1158\/1078-0432.CCR-18-1637","volume":"25","author":"M Lv","year":"2019","unstructured":"Lv M, Wang Y, Chang Y-J, Zhang X-H, Xu L-P, Jiang Q et al (2019) Myeloablative haploidentical transplantation is Superior to Chemotherapy for patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clin Cancer Res 25:1737\u20131748","journal-title":"Clin Cancer Res"},{"key":"5819_CR36","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1182\/blood-2011-11-389809","volume":"119","author":"X-J Huang","year":"2012","unstructured":"Huang X-J, Zhu H-H, Chang Y-J, Xu L-P, Liu D-H, Zhang X-H et al (2012) The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 119:5584\u20135590","journal-title":"Blood"},{"key":"5819_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-018-0598-0","volume":"11","author":"N Santoro","year":"2018","unstructured":"Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A et al (2018) Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol 11:55","journal-title":"J Hematol Oncol"},{"key":"5819_CR38","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","volume":"24","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G et al (2018) Haploidentical transplantation for older patients with Acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 24:1232\u20131236","journal-title":"Biol Blood Marrow Transplant"},{"key":"5819_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00277-016-2864-y","volume":"96","author":"C-L Yu","year":"2017","unstructured":"Yu C-L, Zheng-Dong, Qiao Z-H, Wang J-M, Huang-He, Liang Y-M et al (2017) The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group. Ann Hematol 96:279\u2013288","journal-title":"Ann Hematol"},{"key":"5819_CR40","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41409-018-0279-1","volume":"54","author":"J Sugita","year":"2019","unstructured":"on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT), Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K et al (2019) Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transpl 54:432\u2013441","journal-title":"Bone Marrow Transpl"},{"key":"5819_CR41","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbmt.2015.06.008","volume":"21","author":"J Sugita","year":"2015","unstructured":"Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K et al (2015) HLA-Haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after Busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant 21:1646\u20131652","journal-title":"Biol Blood Marrow Transplant"},{"key":"5819_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8868142","volume":"2021","author":"MM Solh","year":"2021","unstructured":"Solh MM, Hinojosa G, Laporte J, Solomon SR, Morris LE, Zhang X et al (2021) A phase II trial of Melphalan based reduced-intensity conditioning for transplantation of T-Replete HLA-Haploidentical peripheral blood stem cells with Posttransplant Cyclophosphamide in patients with hematologic malignancies. Adv Hematol 2021:1\u20136","journal-title":"Adv Hematol"},{"key":"5819_CR43","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12185-021-03270-z","volume":"115","author":"K Higuchi","year":"2022","unstructured":"Higuchi K, Sawada A, Kondo O, Okada Y, Tsujimoto H, Ioi A et al (2022) HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed\/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis. Int J Hematol 115:406\u2013413","journal-title":"Int J Hematol"},{"key":"5819_CR44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/leu.2013.253","volume":"28","author":"V Bachanova","year":"2014","unstructured":"Bachanova V, Marks DI, Zhang M-J, Wang H, De Lima M, Aljurf MD et al (2014) Ph\u2009+\u2009ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 28:658\u2013665","journal-title":"Leukemia"},{"key":"5819_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12185-019-02660-8","volume":"110","author":"J Sugita","year":"2019","unstructured":"Sugita J (2019) HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol 110:30\u201338","journal-title":"Int J Hematol"},{"key":"5819_CR46","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","volume":"34","author":"N Ghosh","year":"2016","unstructured":"Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN et al (2016) Reduced-intensity transplantation for Lymphomas using Haploidentical Related Donors Versus HLA-Matched Sibling donors: a Center for International Blood and Marrow Transplant Research Analysis. JCO 34:3141\u20133149","journal-title":"JCO"},{"key":"5819_CR47","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A et al (2016) Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 127:938\u2013947","journal-title":"Blood"},{"key":"5819_CR48","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"C Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A et al (2017) Post-transplantation Cyclophosphamide-based Haploidentical Transplantation as Alternative to Matched Sibling or unrelated donor transplantation for Hodgkin Lymphoma: a Registry Study of the Lymphoma Working Party of the European Society for Blood and marrow transplantation. JCO 35:3425\u20133432","journal-title":"JCO"},{"key":"5819_CR49","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","volume":"127","author":"C Kollman","year":"2016","unstructured":"Kollman C, Spellman SR, Zhang M-J, Hassebroek A, Anasetti C, Antin JH et al (2016) The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood 127:260\u2013267","journal-title":"Blood"},{"key":"5819_CR50","doi-asserted-by":"publisher","unstructured":"Dehn J, Deutschland K-R, Perales M-A Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from NMDP\/CIBMTR. https:\/\/doi.org\/10.1182\/blood.2019001212","DOI":"10.1182\/blood.2019001212"},{"key":"5819_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","volume":"55","author":"SO Ciurea","year":"2020","unstructured":"Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang X-J et al (2020) The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl 55:12\u201324","journal-title":"Bone Marrow Transpl"},{"key":"5819_CR52","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","volume":"5","author":"AE DeZern","year":"2021","unstructured":"DeZern AE, Franklin C, Tsai H-L, Imus PH, Cooke KR, Varadhan R et al (2021) Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv 5:1360\u20131368","journal-title":"Blood Adv"},{"key":"5819_CR53","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1182\/bloodadvances.2020001620","volume":"4","author":"J Mariotti","year":"2020","unstructured":"Mariotti J, Raiola AM, Evangelista A, Carella AM, Martino M, Patriarca F et al (2020) Impact of donor age and kinship on clinical outcomes after T-cell\u2013replete haploidentical transplantation with PT-Cy. Blood Adv 4:3900\u20133912","journal-title":"Blood Adv"},{"key":"5819_CR54","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Chang Y-J, Xu L-P, Liu K-Y, Liu D-H, Zhang X-H et al (2014) Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 124:843\u2013850","journal-title":"Blood"},{"key":"5819_CR55","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/ajh.24963","volume":"93","author":"J Canaani","year":"2018","unstructured":"Canaani J, Savani BN, Labopin M, Huang X, Ciceri F, Arcese W et al (2018) Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol 93:246\u2013253","journal-title":"Am J Hematol"},{"key":"5819_CR56","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41409-023-01984-8","volume":"58","author":"A Pruitt","year":"2023","unstructured":"Pruitt A, Gao F, De Togni E, Cochran H, Godbole S, Slade M et al (2023) Impact of donor age and relationship on outcomes of peripheral blood haploidentical hematopoietic cell transplantation. Bone Marrow Transpl 58:855\u2013862","journal-title":"Bone Marrow Transpl"},{"key":"5819_CR57","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12185-022-03342-8","volume":"116","author":"M Teramoto","year":"2022","unstructured":"Teramoto M, Maruyama S, Tamaki H, Kaida K, Mayumi A, Fukunaga K et al (2022) Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation. Int J Hematol 116:248\u2013257","journal-title":"Int J Hematol"},{"key":"5819_CR58","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/ajh.27195","volume":"99","author":"M Teramoto","year":"2024","unstructured":"Teramoto M, Takahashi T, Matsumoto K, Jaber M, Kaida K, Tamaki H et al (2024) Individualized rabbit anti-thymocyte globulin dosing in adult haploidentical hematopoietic cell transplantation with high\u2010risk hematologic malignancy: exposure\u2013response analysis and population pharmacokinetics simulations. Am J Hematol 99:387\u2013395","journal-title":"Am J Hematol"},{"key":"5819_CR59","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","volume":"13","author":"M Bornh\u00e4user","year":"2012","unstructured":"Bornh\u00e4user M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M et al (2012) Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 13:1035\u20131044","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05819-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:08:14Z","timestamp":1722060494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05819-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5819"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05819-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics review committee of the First Affiliated Hospital of Zhejiang University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}